Ewing, B., Hillier, L., Wendl, M
Dosage: 1000 mcg per week (split into 2-3 doses) via subcutaneous injection
It runs deeper than most people understand
no consistent signal for organ toxicity or long-term harm across decades of use Special Populations: Clinical experience exists in elderly patients with dementia and stroke patients, populations where safety data is particularly valuable IV Administration Considerations: Requires clinical administration setting for intravenous dosing, which limits convenience but ensures medical oversight Dihexa: Unknown Human Safety Profile Dihexa has never been administered to humans in any controlled setting, creating a complete absence of human safety data: No Human Pharmacokinetics: Absorption, distribution, metabolism, and excretion parameters are unknown in humans Theoretical c-Met Oncogenesis Concern: The c-Met/HGF pathway is implicated in cancer progression aberrant c-Met signaling promotes tumor growth, metastasis, and angiogenesis in multiple cancer types
Reconstituted peptides require refrigeration and use within 3-4 weeks for optimal stability
